echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sinopharm Hyundai Octreotide Acetate Injection passed the consistency evaluation of generic drugs

    Sinopharm Hyundai Octreotide Acetate Injection passed the consistency evaluation of generic drugs

    • Last Update: 2022-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 15th, Sinopharm Hyundai issued an announcement stating that its holding subsidiary Sinopharm Yixin recently received the "Approval Notice for Supplementary Drug Application" for Octreotide Acetate Injection approved and issued by the National Medical Products Administration, approving the drug to pass the generic drug consistency Evaluation


    Octreotide acetate is a synthetic octapeptide compound that can inhibit the response of luteinizing hormone to gonadotropin releasing hormone, reduce visceral blood flow, inhibit serotonin, gastrin, vasoactive intestinal peptide, chymotrypsin, and motilin , The secretion of glucagon


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.